BAVARIAN NORDIC Shares Outstanding 2016-2021 | BVNRY

BAVARIAN NORDIC shares outstanding from 2016 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
BAVARIAN NORDIC Annual Shares Outstanding
(Millions of Shares)
2020 162
2019 97
2018 97
2017 96
2016 91
2015 86
BAVARIAN NORDIC Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 188
2021-03-31 179
2020-12-31 162
2020-09-30 158
2020-06-30 152
2020-03-31 175
2019-12-31 97
2019-09-30 96
2019-06-30 96
2019-03-31 96
2018-12-31 97
2018-09-30 95
2018-06-30 97
2018-03-31 96
2017-12-31 96
2017-09-30 96
2017-06-30 94
2017-03-31 87
2016-12-31 91
2016-09-30 88
2016-06-30 86
2016-03-31 84
2015-12-31 81
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.431B $0.284B
Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company's product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29